Regenxbio Stock Price. Everything You Need To Know About The Regenxbio Stock!
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 401 full-time employees. The company went IPO on 2015-09-17. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.
Regenxbio Stock Price. Everything You Need To Know About The Regenxbio Stock! performance
- Employees 401
- Company HQ Rockville
- Website https://regenxbio.com/
- RGNX Asset Type Common Stock
- RGNX Market Capitalization 787.6M
- Earnings Per Share -6.02
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Regenxbio is a promising stock that has garnered significant attention in the biotechnology industry. As a reputable investment platform, Zorion is here to guide retail investors from Malaysia, Thailand, Indonesia, and Vietnam on how to invest in Regenxbio from the comfort of their countries. Regenxbio focuses on developing transformative gene therapies to treat a wide range of genetic disorders. With their cutting-edge technology and extensive research, they have gained recognition for their groundbreaking treatments. By investing in Regenxbio, individuals have the opportunity to contribute to revolutionary advancements in healthcare. To invest in Regenxbio from Malaysia, Thailand, Indonesia, and Vietnam, investors can utilize Zorion’s platform, which provides real-time insights, recommendations, and educational resources. By staying informed and leveraging these tools, individuals can make informed investment decisions and potentially benefit from the growth of Regenxbio in the biotechnology sector. Investing in Regenxbio holds promising prospects, and with Zorion’s expertise and resources, retail investors from Malaysia, Thailand, Indonesia, and Vietnam can confidently navigate the journey of investing in this stock. Start your investment journey today and explore the potential offered by Regenxbio with Zorion.
